Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.
|Published (Last):||2 May 2004|
|PDF File Size:||18.82 Mb|
|ePub File Size:||18.1 Mb|
|Price:||Free* [*Free Regsitration Required]|
Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders.
The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment. Esplenuco whose condition progresses even after splenectomy, or those who have a more aggressive tumor, may be successfully managed with chemotherapy, using alkylating agents or purine analogues.
Frecuente anemia y trombocitopenia. Cutaneous recurrence was treated successfully with chemotherapy and maginal but caused fatal hepatitis due to hepatitis B virus reactivation. Es una enfermedad de adultos, con ligero predominio de mujeres.
Procesos linfoproliferativos no Hodgkin de células B
FDR appears to be an efficient therapy with a favorable toxicity profile for patients in relapse after splenectomy or resistant to CLB. There are no specific treatment guidelines for patients for whom splenectomy fails to provide a cure.
The median number of CD20 molecules per cell was 69 x 10 3. The histopathology of splenic lymphoma with villous lymphocytes. The documents contained in this web site are presented for information purposes only.
A clinical comparison of nodal and mucosa-associated lymphoid esplenici types.
A clinicopathological study of 13 cases. Fludarabine is effective in the treatment linfmoa SLVL and should be considered as both a first-line therapeutic option as well as salvage therapy in this condition. Br J Haematol Oct;99 1: World health organization classification of tumours. After treatment, all patients had a complete resolution of splenomegaly along with restoration of their blood counts. However, a few patients relapse and the second-line treatment remains questionable. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
None Sources of funding: Because of the rarity of the disease, there is no established eeplenico therapy.
Detailed information Professionals Review article Deutsch Ten of the 11 patients responded esplrnico rituximab and five of them remained progression-free after a median follow-up of 58 months.
Ten additional patients underwent splenectomy, and 17 patients were in the observation group. One CR and seven minor or good haematological esponses were recorded in relapsed patients.
Linfoma esplénico de la zona marginal
laa Eleven of them had no evidence of disease progression after a median follow-up time of With a median follow-up of 35 month the median overall zoba OS is 40 month and the median progression free survival PFS is 18 month. Because of the indolent course of the disease, monotherapy with rituximab has previously been proposed. Read this article in English. Our results suggest that this schedule is well tolerated and could be an useful alternative to splenectomy.
All patients were assessable: Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. In Julythe patient presented a mass in the lumbar area, a rapid fall in the platelet count and lymphocytosis.
The Integruppo Italiano Linfomi IIL carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic linoma in patients.
Linfoma esplénico de la zona marginal:
The way in which cases of recurrence of splenic marginal zone lymphoma after splenectomy should be managed is still not fully established. Intrasinusoidal bone marrow infiltration: Health care resources for this disease Expert centres Diagnostic tests 59 Patient organisations 45 Orphan drug s Valorar profilaxis con fluconazol mg po.
Two out three patients, who received pentostatin as first line therapy, ttained a complete response CR. The classification must be reproducible and clinically relevant, and sufficiently flexible to permit the incorporation of new data.